A business in context
AGIO research notebook
Read the disclosures. Follow the relationships. Keep the dates in view.
Filing timeline
Download filings CSVReported insider transactions
Download transactions CSVP · PurchaseS · SaleA · Grant / awardM · Exercise / conversionF · Tax / exercise paymentG · Gift
| Transaction / filed | Reporting owner | Type | Security | Shares | Reported price |
|---|---|---|---|---|---|
| 2026-06-18 | Ballal Rahul D. | M · Exercise / conversion | Common stock | 2816.0 | 0.0 |
| 2026-06-18 | Ballal Rahul D. | M · Exercise / conversion | Restricted stock units | 2816.0 | 0.0 |
| 2026-06-18 | Ballal Rahul D. | A · Grant / award | Restricted stock units | 2927.0 | 0.0 |
| 2026-06-18 | Ballal Rahul D. | A · Grant / award | Stock options (right to buy) | 14950.0 | 0.0 |
| 2026-06-18 | CAPELLO JEFFREY D | M · Exercise / conversion | Common stock | 2816.0 | 0.0 |
| 2026-06-18 | CAPELLO JEFFREY D | A · Grant / award | Stock options (right to buy) | 14950.0 | 0.0 |
| 2026-06-18 | CAPELLO JEFFREY D | M · Exercise / conversion | Restricted stock units | 2816.0 | 0.0 |
| 2026-06-18 | CAPELLO JEFFREY D | A · Grant / award | Restricted stock units | 2927.0 | 0.0 |
| 2026-06-18 | Foster-Cheek Kaye I | M · Exercise / conversion | Common stock | 2816.0 | 0.0 |
| 2026-06-18 | Foster-Cheek Kaye I | M · Exercise / conversion | Restricted stock units | 2816.0 | 0.0 |
| 2026-06-18 | Foster-Cheek Kaye I | A · Grant / award | Restricted stock units | 2927.0 | 0.0 |
| 2026-06-18 | Foster-Cheek Kaye I | A · Grant / award | Stock options (right to buy) | 14950.0 | 0.0 |
| 2026-06-18 | FOUSE JACQUALYN A | M · Exercise / conversion | Common stock | 2816.0 | 0.0 |
| 2026-06-18 | FOUSE JACQUALYN A | M · Exercise / conversion | Restricted stock units | 2816.0 | 0.0 |
| 2026-06-18 | FOUSE JACQUALYN A | A · Grant / award | Stock options (right to buy) | 14950.0 | 0.0 |
| 2026-06-18 | FOUSE JACQUALYN A | A · Grant / award | Restricted stock units | 2927.0 | 0.0 |
| 2026-06-18 | Ho Maykin | M · Exercise / conversion | Common stock | 2816.0 | 0.0 |
| 2026-06-18 | Ho Maykin | A · Grant / award | Restricted stock units | 2927.0 | 0.0 |
| 2026-06-18 | Ho Maykin | A · Grant / award | Stock options (right to buy) | 14950.0 | 0.0 |
| 2026-06-18 | Ho Maykin | M · Exercise / conversion | Restricted stock units | 2816.0 | 0.0 |
| 2026-06-18 | Owen Adams Catherine | M · Exercise / conversion | Common stock | 2816.0 | 0.0 |
| 2026-06-18 | Owen Adams Catherine | A · Grant / award | Stock options (right to buy) | 14950.0 | 0.0 |
| 2026-06-18 | Owen Adams Catherine | A · Grant / award | Restricted stock units | 2927.0 | 0.0 |
| 2026-06-18 | Owen Adams Catherine | M · Exercise / conversion | Restricted stock units | 2816.0 | 0.0 |
| 2026-06-18 | Scadden David | M · Exercise / conversion | Common stock | 2816.0 | 0.0 |
| 2026-06-18 | Scadden David | M · Exercise / conversion | Restricted stock units | 2816.0 | 0.0 |
| 2026-06-18 | Scadden David | A · Grant / award | Stock options (right to buy) | 14950.0 | 0.0 |
| 2026-06-18 | Scadden David | A · Grant / award | Restricted stock units | 2927.0 | 0.0 |
| 2026-06-18 | Smith Cynthia | M · Exercise / conversion | Common stock | 2816.0 | 0.0 |
| 2026-06-18 | Smith Cynthia | A · Grant / award | Stock options (right to buy) | 14950.0 | 0.0 |
| 2026-06-18 | Smith Cynthia | M · Exercise / conversion | Restricted stock units | 2816.0 | 0.0 |
| 2026-06-18 | Smith Cynthia | A · Grant / award | Restricted stock units | 2927.0 | 0.0 |
| 2026-06-18 | Viswanadhan Krishnan | A · Grant / award | Restricted stock units | 3000.0 | 0.0 |
| 2026-06-18 | Viswanadhan Krishnan | M · Exercise / conversion | Performance share units | 3000.0 | 0.0 |
| 2026-06-18 | Goff Brian | A · Grant / award | Restricted stock units | 39000.0 | 0.0 |
| 2026-06-18 | Goff Brian | M · Exercise / conversion | Performance share units | 39000.0 | 0.0 |
| 2026-06-18 | Burns James William | A · Grant / award | Restricted stock units | 3000.0 | 0.0 |
| 2026-06-18 | Burns James William | M · Exercise / conversion | Performance share units | 3000.0 | 0.0 |
| 2026-06-18 | Gheuens Sarah | A · Grant / award | Restricted stock units | 3000.0 | 0.0 |
| 2026-06-18 | Gheuens Sarah | M · Exercise / conversion | Performance share units | 3000.0 | 0.0 |
| 2026-06-18 | Jones Cecilia | M · Exercise / conversion | Performance share units | 3000.0 | 0.0 |
| 2026-06-18 | Jones Cecilia | A · Grant / award | Restricted stock units | 3000.0 | 0.0 |
| 2026-06-18 | Milanova Tsveta | A · Grant / award | Restricted stock units | 3000.0 | 0.0 |
| 2026-06-18 | Milanova Tsveta | M · Exercise / conversion | Performance share units | 3000.0 | 0.0 |
| 2026-06-18 | Backstrom Jay T. | A · Grant / award | Stock options (right to buy) | 14950.0 | 0.0 |
| 2026-06-18 | Backstrom Jay T. | A · Grant / award | Restricted stock units | 2927.0 | 0.0 |
| 2026-06-13 | Owen Adams Catherine | M · Exercise / conversion | Common stock | 1976.0 | 0.0 |
| 2026-06-13 | Owen Adams Catherine | M · Exercise / conversion | Restricted stock units | 1976.0 | 0.0 |
| 2026-06-13 | CAPELLO JEFFREY D | M · Exercise / conversion | Common stock | 1976.0 | 0.0 |
| 2026-06-13 | CAPELLO JEFFREY D | M · Exercise / conversion | Restricted stock units | 1976.0 | 0.0 |
Identity & relationships
SEC issuer · 0001439222AGIOS PHARMACEUTICALS, INC.
- Legal Entity Identifier
- 529900ONJHY8EOGYT555
- GLEIF legal name
- Agios Pharmaceuticals, Inc.
- Entity / LEI registration status
- ACTIVE / LAPSED
- Reference data updated
- 2021-07-19T05:07:28Z
Search names and former names
View Wikidata identity and references ↗
- Agios Pharmaceuticals · alias · wikidata
- Agios Pharmaceuticals (United States) · alias · wikidata
- AGIOS PHARMACEUTICALS INC · former SEC name · 2008-07-01 to 2019-07-16
Revenue in constant purchasing power
| Year ended | Reported USD revenue | CPI-adjusted USD revenue |
|---|---|---|
| 2024-12-31 | $36.50M | $38.85M |
| 2023-12-31 | $26.82M | $29.39M |
| 2022-12-31 | $14.24M | $16.25M |
| 2021-12-31 | $0 | $0 |
| 2020-12-31 | $0 | $0 |
| 2019-12-31 | $117.91M | $154.00M |
| 2018-12-31 | $94.39M | $125.51M |
| 2017-12-31 | $43.01M | $58.59M |